146 related articles for article (PubMed ID: 33368804)
21. Subcutaneous oedema of upper limbs heralding an aggressive form of dermatomyositis.
Shukla M; Patel R; Kuzyshyn H; Feinstein D
BMJ Case Rep; 2018 May; 2018():. PubMed ID: 29848519
[TBL] [Abstract][Full Text] [Related]
22. Complement C5-blocking Agent in Refractory Dermatomyositis.
Faguer S; Belliere J; Ribes D
J Rheumatol; 2018 Dec; 45(12):1710-1711. PubMed ID: 30219762
[No Abstract] [Full Text] [Related]
23. Increasing recognition of dermatomyositis with subcutaneous edema - is this a poorer prognostic marker?
Tu J; McLean-Tooke A; Junckerstorff R
Dermatol Online J; 2014 Jan; 20(1):21244. PubMed ID: 24456947
[TBL] [Abstract][Full Text] [Related]
24. Life-threatening systemic capillary leak syndrome in juvenile dermatomyositis.
Meneghel A; Martini G; Birolo C; Tosoni A; Pettenazzo A; Zulian F
Rheumatology (Oxford); 2017 Oct; 56(10):1822-1823. PubMed ID: 28957546
[No Abstract] [Full Text] [Related]
25. Anti-NXP2 antibody-positive dermatomyositis developed after COVID-19 manifesting as type I interferonopathy.
Okada Y; Izumi R; Hosaka T; Watanabe S; Shijo T; Hatchome N; Konishi R; Ichimura Y; Okiyama N; Suzuki N; Misu T; Aoki M
Rheumatology (Oxford); 2022 Apr; 61(4):e90-e92. PubMed ID: 34850853
[No Abstract] [Full Text] [Related]
26. Case report: A case of resistant anti-SAE1 dermatomyositis with severe periorbital edema after hydroxychloroquine that responded to adalimumab.
Farhat M; Soutou B
Int J Rheum Dis; 2024 Mar; 27(3):e15125. PubMed ID: 38501604
[No Abstract] [Full Text] [Related]
27. Primary pulmonary diffuse large B-cell lymphoma with anti-NXP2-positive dermatomyositis: a case report.
Yao F; Deng L; Liao Z; Wen Z
Clin Exp Rheumatol; 2024 Feb; 42(2):454-455. PubMed ID: 37650343
[No Abstract] [Full Text] [Related]
28. [Retrospective analysis of anti-TIF1gamma, anti-NXP2 and anti-SAE1/2 antibodies carriers at Bordeaux university hospital from November 2014 to February 2017].
Victor J; Zanardo L; Héron-Mermin D; Poursac N; Solé G; Bordes C; Duffau P
Rev Med Interne; 2019 Feb; 40(2):70-81. PubMed ID: 30527961
[TBL] [Abstract][Full Text] [Related]
29. Universalis Calcinosis in Adult Dermatomyositis: An "Anti-NXP2 Syndrome".
Fodil D; Meyer A; Salah SS; Sibilia J; Attal N; Tafiani-Lefkir S
J Clin Rheumatol; 2016 Oct; 22(7):387-9. PubMed ID: 27660942
[No Abstract] [Full Text] [Related]
30. Case of pembrolizumab-induced dermatomyositis with anti-transcription intermediary factor 1-γ antibody.
Mizumaki K; Makino S; Ikawa Y; Maeda S; Horii M; Fushida N; Hamaguchi Y; Nohara T; Izumi K; Matsushita T
J Dermatol; 2022 Sep; 49(9):e311-e312. PubMed ID: 35546739
[No Abstract] [Full Text] [Related]
31. [Generalized edema as a form of presentation of juvenile dermatomyositis].
Rodero Prieto R; Camacho Lovillo MS; Lirola Cruz MJ
An Pediatr (Barc); 2013 Oct; 79(4):271-2. PubMed ID: 23477928
[No Abstract] [Full Text] [Related]
32. Recent advances in dermatomyositis-specific autoantibodies.
Fujimoto M; Watanabe R; Ishitsuka Y; Okiyama N
Curr Opin Rheumatol; 2016 Nov; 28(6):636-44. PubMed ID: 27533321
[TBL] [Abstract][Full Text] [Related]
33. Severe macrophage activation syndrome and central nervous system involvement in juvenile dermatomyositis.
Lilleby V; Haydon J; Sanner H; Krossness BK; Ringstad G; Flatø B
Scand J Rheumatol; 2014; 43(2):171-3. PubMed ID: 24588361
[No Abstract] [Full Text] [Related]
34. A 34-year-old man with amyopathic dermatomyositis and rapidly progressive dyspnea with facial swelling. Diagnosis: pneumomediastinum and subcutaneous emphysema secondary to amyopathic dermatomyositis-associated interstitial lung disease.
Powell C; Kendall B; Wernick R; Heffner JE
Chest; 2007 Nov; 132(5):1710-3. PubMed ID: 17998377
[No Abstract] [Full Text] [Related]
35. Acute dermatomyositis with subcutaneous generalized edema.
Werner de Castro GR; Appenzeller S; Bértolo MB; Costallat LT
Clin Rheumatol; 2006 Nov; 25(6):898-900. PubMed ID: 16308667
[TBL] [Abstract][Full Text] [Related]
36. Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juvenile dermatomyositis.
Aouizerate J; De Antonio M; Bader-Meunier B; Barnerias C; Bodemer C; Isapof A; Quartier P; Melki I; Charuel JL; Bassez G; Desguerre I; Gherardi RK; Authier FJ; Gitiaux C
Rheumatology (Oxford); 2018 May; 57(5):873-879. PubMed ID: 29474663
[TBL] [Abstract][Full Text] [Related]
37. [Facial edema and erythroderma in a 54 year-old woman].
Mourguet M; Lajaunie R; Schouler M; Godart M; Bonnet D; Riffaud L; Lamant L; Alric L; Rossi B
Rev Med Interne; 2020 Mar; 41(3):210-213. PubMed ID: 31987672
[No Abstract] [Full Text] [Related]
38. Juvenile dermatomyositis presenting with anasarca.
Mehndiratta S; Banerjee P
Indian Pediatr; 2004 Jul; 41(7):752-3. PubMed ID: 15297701
[No Abstract] [Full Text] [Related]
39. Successful treatment with tocilizumab in a patient with rapidly progressive interstitial lung disease with positive anti-melanoma differentiation-associated gene-5 antibody.
Teng F; Peng JM; Wang Q; Tian XL; Huo Z; Weng L
Chin Med J (Engl); 2020 Nov; 134(8):999-1000. PubMed ID: 33252377
[No Abstract] [Full Text] [Related]
40. [Juvenile dermatomyositis and new autoantibodies: Cases and review].
Guarella M; Jurquet AL; Retornaz K; Bardin N; Chastang MC; Desjonquere M; Fabien N; Belot A
Arch Pediatr; 2015 Dec; 22(12):1263-7. PubMed ID: 26598044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
